A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema
Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema
Sponsor: Opthea Limited
A PHASE1/PHASE2 clinical study on Diabetic Macular Edema, this trial is completed. The trial is conducted by Opthea Limited and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
May 2025 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jul 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
▶ Show 9 earlier versions
-
Sep 2021 — Jul 2022 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1_PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Apr 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2019 — Apr 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2019 — Oct 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2018 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Dec 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Opthea Limited
For direct contact, visit the study record on ClinicalTrials.gov .